Jay Yang

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos et al. · The Lancet Oncology · 2020 · 556 citations · Full text

Lymphoid Neoplasia, Oncology, Malignant Blood Disorder +7

RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability

Dongyi Xu, Rong Guo, Alexandra Sobeck et al. · Genes & Development · 2008 · 212 citations · Full text

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

David P. Steensma, Martin Wermke, Virginia M. Klimek et al. · Leukemia · 2021 · 169 citations · Full text

Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation

Dongyi Xu, Weiping Shen, Rong Guo et al. · Nature Neuroscience · 2013 · 149 citations · Full text

Molecular Neuroscience, Synapse Formation, Fragile X Spectrum +4

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Marjorie G. Zauderer, Peter W. Szlosarek, Sylvestre Le Moulec et al. · The Lancet Oncology · 2022 · 119 citations

Ezh2 Inhibitor Tazemetostat, Malignant Disease, Medicine +7